Cantabio Pharmaceuticals Stock Performance
| CTBO Stock | USD 1.01 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Cantabio Pharmaceuticals are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Cantabio Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy fundamental drivers, Cantabio Pharmaceuticals is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
Cantabio |
Cantabio Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 101.00 in Cantabio Pharmaceuticals on October 18, 2025 and sell it today you would earn a total of 0.00 from holding Cantabio Pharmaceuticals or generate 0.0% return on investment over 90 days. Cantabio Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Cantabio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cantabio Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cantabio Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Cantabio Pharmaceuticals, and traders can use it to determine the average amount a Cantabio Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| CTBO |
Based on monthly moving average Cantabio Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cantabio Pharmaceuticals by adding Cantabio Pharmaceuticals to a well-diversified portfolio.
Cantabio Pharmaceuticals Fundamentals Growth
Cantabio Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Cantabio Pharmaceuticals, and Cantabio Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cantabio Pink Sheet performance.
| Return On Asset | -4.71 | |||
| Current Valuation | 1.69 M | |||
| Shares Outstanding | 22.54 K | |||
| Price To Earning | (1.00) X | |||
| EBITDA | (1.39 M) | |||
| Cash And Equivalents | 283.37 K | |||
| Cash Per Share | 12.57 X | |||
| Book Value Per Share | (97.77) X | |||
| Cash Flow From Operations | (623.35 K) | |||
| Earnings Per Share | (130.83) X | |||
| Total Asset | 109.43 K | |||
| Retained Earnings | (996 K) | |||
| Current Asset | 52 K | |||
| Current Liabilities | 422 K | |||
About Cantabio Pharmaceuticals Performance
By examining Cantabio Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Cantabio Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Cantabio Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinsons disease , Alzheimers disease , and other related diseases. The company was founded in 2009 and is based in Palo Alto, California. Cantabio Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Cantabio Pharmaceuticals performance evaluation
Checking the ongoing alerts about Cantabio Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Cantabio Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cantabio Pharmaceuticals generated a negative expected return over the last 90 days | |
| Cantabio Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Cantabio Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company has a current ratio of 0.15, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cantabio Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Cantabio Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cantabio Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cantabio to invest in growth at high rates of return. When we think about Cantabio Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (2.01 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cantabio Pharmaceuticals currently holds about 283.37 K in cash with (623.35 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.57, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 70.0% of the company shares are held by company insiders |
- Analyzing Cantabio Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cantabio Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Cantabio Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cantabio Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cantabio Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cantabio Pharmaceuticals' pink sheet. These opinions can provide insight into Cantabio Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Cantabio Pink Sheet
Cantabio Pharmaceuticals financial ratios help investors to determine whether Cantabio Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cantabio with respect to the benefits of owning Cantabio Pharmaceuticals security.